Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

NCT03450057 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Daratumumab with dexamethasone

Sponsor

Hellenic Society of Hematology

Collaborators

[object Object]